State Of New Jersey Common Pension Fund D Iovance Biotherapeutics, Inc. Transaction History

State Of New Jersey Common Pension Fund D

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	BUY	$7.59 - $17.47 $1.27 Million - $2.93 Million	167,959 New	167,959 $2.49 Million
Q2 2023 Aug 02, 2023	BUY	$5.36 - $9.06 $1.47 Million - $2.48 Million	274,122 New	274,122 $1.93 Million
Q3 2022 Oct 28, 2022	BUY	$9.53 - $13.11 $590,478 - $812,295	61,960 Added 42.08%	209,187 $2 Million
Q2 2022 Aug 04, 2022	SELL	$6.38 - $18.33 $100,242 - $288,000	-15,712 Reduced 9.64%	147,227 $1.63 Million
Q1 2022 May 03, 2022	BUY	$12.38 - $19.1 $170,621 - $263,236	13,782 Added 9.24%	162,939 $2.71 Million
Q4 2021 Jan 31, 2022	BUY	$16.55 - $27.63 $327,342 - $546,493	19,779 Added 15.29%	149,157 $2.85 Million
Q3 2021 Oct 27, 2021	BUY	$20.35 - $26.63 $756,816 - $990,369	37,190 Added 40.34%	129,378 $3.19 Million
Q2 2021 Jul 23, 2021	BUY	$16.33 - $33.07 $377,304 - $764,082	23,105 Added 33.45%	92,188 $2.4 Million
Q1 2021 Apr 27, 2021	SELL	$28.67 - $52.59 $68,263 - $125,216	-2,381 Reduced 3.33%	69,083 $2.19 Million
Q4 2020 Feb 03, 2021	SELL	$28.04 - $50.26 $170,314 - $305,279	-6,074 Reduced 7.83%	71,464 $3.32 Million
Q3 2020 Oct 27, 2020	BUY	$27.75 - $36.3 $243,978 - $319,149	8,792 Added 12.79%	77,538 $2.55 Million
Q2 2020 Aug 04, 2020	SELL	$27.21 - $41.0 $865,958 - $1.3 Million	-31,825 Reduced 31.64%	68,746 $1.89 Million
Q4 2019 Jan 31, 2020	BUY	$17.95 - $29.41 $78,459 - $128,551	4,371 Added 4.54%	100,571 $2.78 Million
Q3 2019 Oct 23, 2019	BUY	$17.99 - $26.0 $1.73 Million - $2.5 Million	96,200 New	96,200 $1.75 Million

323

239M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.48B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.